WVXU: Ohio Innocence Project fighting to clear Milford man after 11 years in prison
UC law professor appears on 'Cincinnati Edition' to discuss new DNA evidence discovered by OIP in case of man convicted of robbery
Further action is required to make this image accessible
One of the below criteria must be satisfied:
- Add image alt tag OR
- Mark image as decorative
The image will not display on the live site until the issue above is resolved.
Donald Caster. File photo
Donald Caster, an assistant professor of clinical law at the University of Cincinnati College of Law and attorney with UC’s Ohio Innocence Project, will appear on WVXU’s Cincinnati Edition to discuss the OIP’s efforts in the case of a local man convicted of robbery.
Caster and WCPO journalist Paula Christian will discuss the case of Kevin Thornton, a Milford man who served 11 years in prison after being convicted of robbery. He now lives in a halfway house. Attorneys with the OIP say they’ve discovered DNA evidence that indicates Thornton did not rob the Cash Express store in 2007 for which he was convicted.
Read more about the story and listen to audio of segment here.
Related Stories
UC faculty and staff among Rising Star leadership honorees
January 5, 2026
Two UC faculty and staff members are among this year's Rising Star leadership program sponsored by YWCA Greater Cincinnati. Kelli Beecher, assistant professor in the UC College of Nursing, and Brittany Bibb, assistant director of programs and operations in the UC Division of Student Affairs, are among the emerging leaders of 2026. They were featured in the publication Movers & Makers.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.